Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.

ABSTRACT:

Background

Genetic testing for cancer predisposition is recommended to women with breast cancer who meet the criteria for such testing. After the FDA approvals of the poly ADP ribose polymerase (PARP) inhibitors, olaparib and talazoparib, for treatment of metastatic breast cancer, carrying germline mutations in BRCA1 and BRCA2 genes, the genetic testing result has become critical in their care. With the recent FDA approval of alpelisib for the treatment of PIK3CA-mutated hormone-receptor positive metastatic breast cancer, tumor molecular profiling to identify somatic mutations and potential molecularly targeted agents is increasingly utilized in the treatment of advanced breast cancer.

Aim

Combining germline and somatic sequencing (paired testing) offers an advantage over a

SUBMITTER: Elliott E 

PROVIDER: S-EPMC7941483 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature